GZBL(SZ:002424) Zheng Quan Ri Bao Zhi Sheng·2025-10-16 04:39Core Viewpoint - Guizhou BaiLing Pharmaceutical Group's subsidiary has received approval for clinical trials of a new traditional Chinese medicine, Tang Ning Tong Luo Pian, aimed at treating Type 2 Diabetes Mellitus (T2DM) and its complications, marking a significant advancement in the company's strategy in the metabolic disease sector [1][2][4] Group 1: Product Development - Tang Ning Tong Luo Pian is the first traditional Chinese medicine to enter clinical trials for both diabetes treatment and its complications in China [1] - The drug has shown promising pharmacological effects by adjusting endocrine functions and improving biochemical indicators in T2DM patients [1][2] - The development of Tang Ning Tong Luo Pian addresses the clinical needs for diabetes prevention, treatment, and management of complications [2][4] Group 2: Market Context - The global diabetes patient population is projected to reach 589 million by 2024, with China having 148 million patients, the highest in the world [2] - The diabetes medication market in China is expected to grow significantly, reaching 116.1 billion yuan by 2025 and 167.5 billion yuan by 2030 [3] - Despite the large market size, a significant portion is dominated by imported drugs, indicating a gap in meeting clinical needs [3] Group 3: Competitive Advantage - Tang Ning Tong Luo Pian is based on Miao medicine principles and has demonstrated unique advantages in treating diabetes and its complications through modern research methods [3][4] - The drug has shown effectiveness in lowering glycosylated hemoglobin levels and delaying the progression of diabetic retinopathy and other complications [3] - If approved, capturing just 1% of the market could yield approximately 2 billion yuan in sales, highlighting its potential impact [4] Group 4: Strategic Vision - The company aims to establish a comprehensive approach to diabetes management through Tang Ning Tong Luo Pian, addressing both prevention and treatment of complications [4] - The chairman of the company emphasized the innovative model of integrating traditional medicine with modern research to enhance the global reach of ethnic medicine [4]